Avidity Biosciences (RNA) EBT Margin (2019 - 2025)
Historic EBT Margin for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to 1395.29%.
- Avidity Biosciences' EBT Margin rose 20364800.0% to 1395.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 2628.53%, marking a year-over-year increase of 1384400.0%. This contributed to the annual value of 2955.44% for FY2024, which is 7417800.0% down from last year.
- Per Avidity Biosciences' latest filing, its EBT Margin stood at 1395.29% for Q3 2025, which was up 20364800.0% from 4072.37% recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' EBT Margin ranged from a high of 881.69% in Q1 2021 and a low of 7332.36% during Q1 2025
- In the last 5 years, Avidity Biosciences' EBT Margin had a median value of 2023.45% in 2023 and averaged 2470.78%.
- Over the last 5 years, Avidity Biosciences' EBT Margin had its largest YoY gain of 20364800bps in 2025, and its largest YoY loss of -53918000bps in 2025.
- Quarter analysis of 5 years shows Avidity Biosciences' EBT Margin stood at 2078.4% in 2021, then increased by 12bps to 1822.07% in 2022, then crashed by -51bps to 2751.39% in 2023, then decreased by -25bps to 3446.28% in 2024, then surged by 60bps to 1395.29% in 2025.
- Its EBT Margin stands at 1395.29% for Q3 2025, versus 4072.37% for Q2 2025 and 7332.36% for Q1 2025.